Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semax

ACTH(4-10) analogue, Heptapeptide SEMAX

Quick Stats
Studies 172
Trials 37
Score 2
2016 pubmed 13 citations

Synacton and individual activity of synthetic and natural corticotropins.

Vyunova. T V TV; Andreeva. L A LA; Shevchenko. K V KV; Myasoedov. N F NF

Key Findings

  • Semax’s benefits come from a mix of its original form and its breakdown products, called a “synacton.”
  • The metabolites HFPGP and PGP have their own binding sites on neuronal membranes and show strong competitive activity, especially the 5‑amino‑acid fragments EHFPG and HFPGP.
  • Peptide‑membrane interactions aren’t limited to a single classic binding spot, suggesting a broader regulatory potential.

Practical Outcomes

  • For biohackers, this means Semax’s effects likely stem from several active fragments, not just the parent peptide. While the paper doesn’t change how you dose Semax, it supports the idea that the peptide’s complex metabolism contributes to its cognitive benefits, and future formulations might aim to include or enhance these key fragments.

Summary

The study shows that the brain‑boosting peptide Semax works not just as a single molecule but as a group of related fragments that together create its effects. Two main breakdown pieces, HFPGP and PGP, bind to brain cell membranes and help explain why Semax can influence many brain functions, but the research doesn’t give clear dosing tips or new ways to use it.

Abstract

Short endogenous peptides represent one of the most important constituents of the mammalian body's general regulatory system. Some synthesized analogs and modified natural peptides (eg, corticotropins) also show high biological activity. Nevertheless, the mechanism of action of regulatory peptides remains unclear. To explain the effects of peptides of intermolecular processes, the hypothesis that a synactonal mechanism underlies the action of regulatory peptides, exemplified by the heptapeptide Semax, has been proposed. Thus, in the total pool of Semax metabolites, which includes the cleavage products of the parental molecule, we can distinguish the functional core, represented by the major metabolic products-peptides HFPGP and PGP. These peptides have their own binding sites with similar although differing characteristics. Together with Semax, they constitute a single complex of bioregulators acting in a certain sequence and in interaction, ie, synacton. It can be assumed that the diverse clinically significant effects of the drug Semax are determined by its synacton. Specific interactions between some tritium-labeled peptides (basic constituents of the Semax synacton) and plasma membranes of neurons have been characterized. Only a few peptides of the Semax synacton showed competitive activity for the Semax binding sites. Fragments comprising 5 amino acid residues (EHFPG and HFPGP) showed the highest competitive activity. We also characterized the processes of specific ligand-receptor interactions of some tritium-labeled corticotropins ([<sup>3</sup> H-Pro]MEHFPGP, [<sup>3</sup> H-Pro]HFPGP, and [<sup>3</sup> H-Pro]PGP) by applying mathematical discriminative models (Scatchard, Hill, Bjerrum, and Lineweaver-Burk plots). So the intermolecular interactions of these peptides with plasma membranes of neuronal brain targets are probably not limited by specific binding at orthosteric sites. The effect of peptides that act in the synacton considerably extends the regulatory potential of the initial molecule.

Study Information

Provider

pubmed

Year

2016

Date

2016-12-06T00:00:00.000Z

DOI

10.1002/jmr.2597

Citations

13

References

31